Business brief
Corporate Pivots and Valuation Realities
Tesla scraps Cybertruck for robotaxis, Anthropic hits IPO valuation pushback, and Moderna proves mRNA commercial viability beyond vaccines.
Business
Tesla will cancel Cybertruck production by mid-2027 — scrapping its niche steel pickup to bet the company's factory floor on autonomous robotaxis.
BackgroundTesla unveiled the stainless-steel Cybertruck in 2019, targeting 250,000 annual deliveries to challenge dominant Detroit internal-combustion pickups. Severe manufacturing complications with cold-rolled steel and softening consumer demand resulted in a 48% sales slump throughout 2025.
- Manufacturing capacity at the Austin Gigafactory will transition directly to building dedicated two-seat Cybercab robotaxis lacking steering wheels and pedals.
- The Cybertruck reached roughly 71,000 lifetime deliveries since late 2023, falling far short of initial commercial scale targets.
- The decision mirrors Tesla's previous discontinuation of Model S and Model X assembly lines to reallocate capital toward Optimus humanoid robotics.
Business
Wall Street investors balked at Anthropic's $1.5T valuation — demanding a discount toward $1T before absorbing the largest IPO in market history.
BackgroundAnthropic expanded rapidly on surging enterprise demand for its Claude models, reaching an annualized revenue run rate exceeding $80 billion by late October. Wall Street investment banks planned to execute the largest initial public offering in financial history ahead of Thanksgiving.
- Sovereign wealth and institutional funds indicated pricing must compress closer to $1 trillion to absorb the planned multi-billion-dollar share float.
- Underwriters and advisers are debating whether to trim the capital raise to $80 billion or delay the listing until tech volatility stabilizes.
- The valuation dispute reflects growing institutional investor reluctance to pay peak revenue multiples amid heavy computational infrastructure capital spending.
Business
Moderna swung back into profitability and hiked guidance to 25% — proving mRNA commercial viability can extend beyond emergency pandemic boosters into oncology.
BackgroundModerna struggled with steep post-pandemic revenue declines and massive research overhead as demand for COVID-19 boosters plummeted from 2022 peaks. The biotechnology pioneer trimmed annual operational expenditures to $2.7 billion while pivoting mRNA technology toward individualized oncology treatments.
- Third-quarter revenue reached $1.31B, up 29% year over year, generating diluted earnings of $0.38 per share compared to a net loss last year.
- Management lifted fiscal 2026 sales growth guidance from an initial 10% ceiling to a range between 15% and 25%, beating Wall Street forecasts.
- Clinical momentum was bolstered by Phase 3 data showing individualized melanoma therapy intismeran reduced recurrence or death risks by 42% when combined with Keytruda.
Business
Cloudflare rallied 19% on 39% revenue growth — demonstrating that enterprise security and distributed AI inference are translating into accelerating cloud sales.
BackgroundCloudflare provides distributed edge network infrastructure, website protection, and developer tools across thousands of data points worldwide. Enterprise adoption of artificial intelligence applications has expanded demand for low-latency security firewalls and serverless edge computing.
- Adjusted earnings per share reached $0.38, exceeding analyst expectations of $0.34 alongside record enterprise client additions.
- Management raised full-year 2026 revenue guidance to over $2.96B, anticipating continued demand for automated cybersecurity suites.
- Chief Executive Matthew Prince called the period Cloudflare's strongest quarter on record, citing enterprise migrations to Workers AI edge infrastructure.
Business
Business
Business
Business
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
